Insider trade

10% owner sold ~$160K of JNJ shares in the open market

Traded Nov 25, 2025 · Filed Jan 8, 2026

Johnson & JohnsonJNJ

~$160K
Reported value · 16K sh @ $10.03: 4.03M
Holds after · shares reported: +25.2%
stock since the trade · S&P 500 +13.2%, $206.67 → $258.66 on Oct 1

Why it stands out

A big owner of Johnson & Johnson sold $160K of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 25, 2025
Reporting period: Not applicable
Filed with the SEC: Jan 8, 2026

10% ownerIndirect holding$100K–$500K

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$160,480

Shares × reported transaction price

Timing vs results

42 days after results of Oct 14, 2025, 57 days before results of Jan 21, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $206.67 on Nov 25, 2025, at its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $142.06 (Jan 10, 2025) to $206.67 (Nov 25, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $190.85 on Oct 14, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Darzalex Faspro on Nov 19, 2025, 6 days before this trade.

New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+7.0%	-0.3%	+7.3%
30 days	+16.8%	-0.0%	+16.8%
90 days	+18.1%	-2.0%	+20.1%
180 days	+28.9%	+7.4%	+21.5%

Past results only. Not a forecast.

Source receipt

Record ID: 0001193125-26-007679
Filed / recorded: Jan 8, 2026, 9:05 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Needs review
Issuer: CVRx, Inc.
Issuer CIK: 1235912
Ticker: CVRX
Reporting person: JOHNSON & JOHNSON
Relationship: 10% owner
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Nov 25, 2025
Transaction code: S
Shares / units: 16,000
Price per share: $10.03
Acquired / disposed: Disposed (D)
Shares owned after: 4,031,198
Ownership form: Indirect — By Johnson & Johnson Innovation - JJDC, Inc.
Amendment: Yes (Form 4/A)

Footnotes from the filing

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.22. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The securities reported as being indirectly beneficially owned by Johnson & Johnson, the designated Reporting Person, are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc. ("JJDC"). JJDC is a wholly-owned subsidiary of Johnson & Johnson.